Syndax Pharmaceuticals Inc (SNDX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.62 (-0.34%), Market cap $2.10B, 52-week low–high $8.73 ~ $25.15.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmo
Financial statements, price targets, institutional (13F) holdings and related news for Syndax Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Syndax Pharmaceuticals Inc trades at $17.62 (-0.34%). Real-time quotes and charts are available on BlackAll Trade.
Syndax Pharmaceuticals Inc has a market cap of about $2.10B.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor